Serial No.: 10/024,520

Amendments to the Claims

The following Listing of Claims replaces all prior versions and listings of claims in this application:

Listing of Claims:

- 1. (Currently Amended) A pharmaceutical tablet composition comprising an effective amount of crystalline Form I amlodipine free base and at least one pharmaceutically acceptable excipient; wherein said amlodipine free base is selected from the group consisting of crystalline Form I amlodipine free base, crystalline Form II amlodipine free base, and mixtures thereof; and wherein said tablet leaves an average residue of amlodipine on the tablet punch of 0.7 μg·cm⁻² per tablet or less.
- 2. (Cancelled)
- 3. (Original) The composition according to claim 1, wherein said excipient is a calcium phosphate.
- 4. (Original) The composition according to claim 1, wherein said excipient is microcrystalline cellulose.
- 5. (Original) The composition according to claim 3, which further comprises microcrystalline cellulose.
- 6. (Original) The composition according to claim 5, wherein said calcium phosphate is anhydrous calcium hydrogen phosphate.
- 7.-9. (Cancelled)

Serial No.: 10/024,520

10. (Original) The composition according to claim 1, wherein said tablet contains 1 to 100 mg of said amlodipine free base.

- 11. (Cancelled)
- 12. (Previously Presented) A method of treating or preventing hypertension, angina, or congestive heart failure, which comprises administering the composition according to claim 1 to a patient in need thereof.
- 13.-34 (Cancelled)
- 35. (Previously Presented) The composition according to claim 1, wherein said amlodipine free base was incorporated into said composition in the form of particulates having an average particle size of at least 100 microns.
- 36. (Previously Presented) The composition according to claim 35, wherein said average particle size is 150-350 microns.
- 37. (Previously Presented) The composition according to claim 36, wherein said average particle size is 200-300 microns.
- 38. (Cancelled)
- 39. (Previously Presented) The composition according to claim 35, wherein said excipient is anhydrous calcium hydrogen phosphate.
- 40. (Previously Presented) The composition according to claim 36, wherein said excipient is anhydrous calcium hydrogen phosphate and said composition further comprises microcrystalline cellulose; and wherein said tablet leaves an average residue on the tablet punch of 0.6 μg/cm² per tablet or less.

Serial No.: 10/024,520

41. (Previously Presented) The composition according to claim 1, wherein said composition is in the form of a round tablet.

- 42. (Previously Presented) The composition according to claim 41, wherein said tablet is a round tablet having a diameter of about 20 mm.
- 43. (Currently Amended) An oral pharmaceutical tablet composition comprising an effective amount of crystalline Form I amlodipine free base and at least one pharmaceutically acceptable excipient; wherein said tablet leaves an average residue of amlodipine on the tablet punch of 0.7 μg·cm⁻² per tablet or less.
- 44. (Withdrawn) The pharmaceutical composition according to claim 43, which further comprises an ACE-inhibitor or a cholesterol-lowering agent.
- 45. (Withdrawn) The pharmaceutical composition according to claim 44, wherein said ACE-inhibitor is benazepril and said cholesterol-lowering agent is selected from lovastatin, simvastatin, and atorvastatin.
- 46. (Withdrawn). The pharmaceutical composition according to claim 45, wherein said composition comprises said cholesterol-lowering agent selected from lovastatin, simvastatin, and atorvastatin.

47-50. (Cancelled)

- 51. (Withdrawn) The pharmaceutical composition according to claim 43, which further comprises benazepril hydrochloride.
- 52. (Cancelled)